The abstract shows that biomarker-cognition relationships vary dramatically by drug mechanism (strong for anti-amyloid, weak for anti-tau). Establishing surrogacy relationships is critical for accelerating drug development, but the mechanistic basis for these differences remains unclear. Gap type: open_question Source paper: Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review. (2024, Alzheimer's research & therapy, PMID:38678292)
Landscape Summary: Which fluid biomarkers can serve as valid surrogates for cognitive outcomes across different drug targets? is a 0.83 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Which fluid biomarkers can serve as valid surrogates for cognitive outcomes across different drug targets? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: